Biliary cancer: Utility of next-generation sequencing for clinical management

Cancer

Volumn 122, Issue 24, 2016, Pages 3838-3847

  Javle, Milind ^a   Bekaii Saab, Tanios ^b   Jain, Apurva ^a   Wang, Ying ^a   Kelley, Robin Katie ^c   Wang, Kai ^d   Kang, Hyunseon C ^a   Catenacci, Daniel ^e   Ali, Siraj ^d   Krishnan, Sunil ^a   Ahn, Daniel ^b   Bocobo, Andrea Grace ^c   Zuo, Mingxin ^a   Kaseb, Ahmed ^a   Miller, Vincent ^d   Stephens, Philip J ^d   Meric Bernstam, Funda ^a   Shroff, Rachna ^a   Ross, Jeffrey ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FOUNDATION MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

Author keywords

AT rich interactive domain containing protein 1A (ARID1A); biliary tract cancers; comprehensive genomic profiling; fibroblast growth factor receptor 2 (FGFR2); isocitrate dehydrogenase 1 2 (IDH1 2); prognosis; targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FIBROBLAST GROWTH FACTOR RECEPTOR 2; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; SMAD4 PROTEIN; CYCLIN DEPENDENT KINASE; TUMOR PROTEIN;

ADULT; ARID1A GENE; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CDKN2A GENE; CDKN2B GENE; CONTROLLED STUDY; FEMALE; FGFR2 GENE; GALLBLADDER CARCINOMA; GENE; GENE MUTATION; HUMAN; IDH1 GENE; IDH2 GENE; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; SMAD4 GENE; TUMOR SUPPRESSOR GENE; BILE DUCT NEOPLASMS; GALLBLADDER TUMOR; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES; SIGNAL TRANSDUCTION;

BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CYCLIN-DEPENDENT KINASES; FEMALE; GALLBLADDER NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84992509268     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30254     Document Type: Article

References (51)

1. Augustine MM, Fong Y. Epidemiology and risk factors of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:171–188.
2. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–1378.
3. Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110:585–591.
4. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512–522.
5. Charbel H, Al-Kawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep. 2011;13:182–187.
6. Dickson PV, Behrman SW. Distal cholangiocarcinoma. Surg Clin N Am. 2014;94:325–342.
7. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11:13–21.e11.
8. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–2179.
9. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–1229.
10. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125.
11. Brown KM, Geller DA. Proximal biliary tumors. Surg Clin N Am. 2014;94:311–323.
12. Takahashi Y, Ebata T, Yokoyama Y, et al. Surgery for recurrent biliary tract cancer: a single-center experience with 74 consecutive resections. Ann Surg. 2015;262:121–129.
13. Wernberg JA, Lucarelli DD. Gallbladder cancer. Surg Clin N Am. 2014;94:343–360.
14. Ciombor KK, Goff LW. Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol. 2013;11:28–34.
15. Robertson S, Hyder O, Dodson R, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013;44:2768–2773.
16. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96:896–902.
17. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008;13:415–423.
18. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–1940.
19. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28:266–272.
20. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013;44:1216–1222.
21. Weindel M, Zulfiqar M, Bhalla A, Shidham VB. Molecular diagnostics in the neoplasms of the pancreas, liver, gall bladder, and extrahepatic biliary tract. Clin Lab Med. 2013;33:875–880.
22. Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–1434.
23. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10:e1004135.
24. Lee H, Wang K, Johnson A, et al. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016;69:403–408.
25. Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19:235–242.
26. Stephens P, Wang K, Palma NA, et al. Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy [abstract 4142]. J Clin Oncol. 2014;32(suppl):5s.
27. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–647.
28. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–1031.
29. Compeau PE, Pevzner PA, Tesler G. How to apply de Bruijn graphs to genome assembly. Nat Biotechnol. 2011;29:987–991.
30. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945–D950.
31. Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696.
32. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021–1031.e15.
33. Andersen JB, Thorgeirsson SS. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol. 2014;1:143–157.
34. Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 2012;19:326–336.
35. Geynisman DM, Catenacci DV. Toward personalized treatment of advanced biliary tract cancers. Discov Med. 2012;14:41–57.
36. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531–3540.
37. Marino D, Leone F, Cavalloni G, Cagnazzo C, Aglietta M. Biliary tract carcinomas: from chemotherapy to targeted therapy. Crit Rev Oncol Hematol. 2013;85:136–148.
38. Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9:e115383.
39. Malats N, Porta M, Pinol JL, Corominas JM, Rifa J, Real FX. Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators. J Clin Oncol. 1995;13:1679–1686.
40. Milind M, Javle RTS, Andrew Z, Saeed S, SuPin C, Mitesh JB, Maeve AL, Anthony E-K, Teresa M, Philip AP, Do-Youn O, Eric VC, Kun-Huei Y, Randi I, Carolyn M, Suman S, Tanios SB-S. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. Poster presented at 2016 Gastrointestinal Cancers Symposium; 2016 Jan, San Francisco, California.
41. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339–344.
42. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932–941.
43. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552–1558.
44. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829–840.
45. Goyal L, Govindan A, Sheth RA, et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015;20:1019–1027.
46. Burris H, Mellinghoff I, Maher E, et al. Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas. Mol Cancer Ther. 2015;14(12 Supplement 2):PL04−05.
47. Harder J, Waiz O, Otto F, et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol. 2009;15:4511–4517.
48. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J. Pathol. 2005;206:356–365.
49. Kim HJ, Yoo TW, Park DI, et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann Oncol. 2007;18:892–897.
50. Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. Am J Hematol Oncol. 2015;8:58.
51. Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012;109:14476–14481.